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Summary14
The rise of antibiotic resistance threatens modern medicine; to combat it new diagnos-15
tic methods are required. Sequencing the whole genome of a pathogen offers the potential16
to accurately determine which antibiotics will be effective to treat a patient. A key limi-17
tation of this approach is that it cannot classify rare or previously unseen mutations. Here18
we demonstrate that alchemical free energy methods, a well-established class of methods19
from computational chemistry, can successfully predict whether mutations in Staphylococ-20
cus aureus dihydrofolate reductase confer resistance to trimethoprim. We also show that21
the method is quantitively accurate by calculating how much the most common resistance-22
conferring mutation, F99Y, reduces the binding free energy of trimethoprim and compar-23
ing predicted and experimentally-measured minimum inhibitory concentrations for seven24
different mutations. Finally, by considering up to 32 free energy calculations for each mu-25
tation, we estimate its specificity and sensitivity. [143 words]26
INTRODUCTION27
Resistance of bacteria to the antibiotics used to treat them is a substantial and growing global28
threat to human health (Davies, 2013; World Economic Forum, 2013). Measures to counter29
the emergence of antibiotic resistance are restricted by the limitations of conventional diagnos-30
tic microbiology. This predominantly still relies on culture-based, phenotypic identification of31
bacteria followed by growth in the presence of different antibiotic concentrations to detect re-32
sistance. The process is labour intensive, takes days or even weeks depending on the growth33
rate of the organism in question, is expensive and open to subjective interpretation. Genetic ap-34
proaches, particularly those based on sequencing the entire genome of a pathogen (Didelot et al.,35
2012; Köser et al., 2014), have the potential to be faster and cheaper. Inferring the phenotype36
of an infecting pathogen from whole-genome sequence data by considering known resistance37
genes or mutations has already been shown to be reasonably accurate for a range of pathogens38
(Gordon et al., 2014; Walker et al., 2015; Pankhurst et al., 2016; Bradley et al., 2015) and has39
recently been implemented in the U.K. for the routine diagnosis of M. tuberculosis infections40
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(Walker et al., 2017). New mutations, however, continually arise and a genetics-based clinical41
microbiology service therefore also needs to be able to predict the effect of novel mutations. In42
this paper we demonstrate that molecular-based computational chemistry methods can predict43
whether individual protein mutations confer resistance to an antibiotic.44
As proof of principle we have investigated the effect of mutations to Staphylococcus au-45
reus dihydrofolate reductase (DHFR) on the binding of the antibiotic trimethoprim (TMP, Fig.46
1A). S. aureus is a clinically important gram-positive pathogen and has been the focus of much47
research due to the development of methicillin- and vancomycin-resistant strains, known as48
MRSA and VRSA, respectively. TMP, usually administered as co-trimoxazole (trimethoprim-49
sulfamethoxazole), has a long history of treating S. aureus infections (Tong et al., 2015) in-50
cluding common skin and soft tissue infections caused by MRSA strains (Nurjadi et al., 2014).51
TMP competes with the natural substrate, dihydrofolic acid (DHA, Fig. 1A), for binding to52
DHFR, thereby preventing DHFR catalyzing the conversion of DHA to tetrahydrofolic acid.53
Since tetrahydrofolate is essential for the biosynthesis of thymidylate, purine nucleotides, and54
some amino acids, arresting the production of DHA inhibits bacterial growth. Resistance to55
TMP in S. aureus can either arise from mutations in the chromosomal gene dfrB, or from the56
introduction of other naturally-resistant genes (dfrA, dfrG and dfrK) via plasmids (Lowy, 2003;57
Nurjadi et al., 2014). Here we focus on seven mutations in the dfrB chromosomal gene. We have58
chosen this gene for five reasons: (i) a series of resistance-conferring and no-effect mutations59
have been identified via whole-genome sequencing of isolates from patient infections (Gordon60
et al., 2014), as well as by more traditional methods, (ii) the most common resistance-conferring61
mutation is a very small chemical change (Phe! Tyr) and this is therefore a challenging test62
for any predictive approach, (iii) DHFR is a small, soluble protein that has been well-studied,63
(iv) several experimental structures exist of S. aureus DHFR bound to TMP (Fig. 1B) (Dale64
et al., 1997; Oefner et al., 2009; Heaslet et al., 2009) and (v) there is published quantitative65
biophysical data on how the most common resistant-conferring mutation in S. aureus affects66
the binding of TMP to DHFR (Pires et al., 2015; Oefner et al., 2009; Dale et al., 1997; Frey67
et al., 2010, 2012). Since this is a classification problem we emphasise the importance of hav-68
ing negative controls (that is, mutations that are known to have no effect). This underscores the69
vital importance of clinical whole genome sequencing studies as these naturally identify large70
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numbers of such mutations.71
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Figure 1: Seven mutations in S. aureus dihydrofolate reductase (DHFR) were chosen from a
whole genome sequencing study of clinical isolates (Gordon et al., 2014) to test our approach
(A) Trimethoprim (TMP) competes with the natural substrate, dihydrofolic acid (DHA), for
binding to DHFR, thereby inhibiting the action of this essential protein. (B) A structure of
chromosomal S. aureus DHFR (dfrB) bound with TMP and NADPH, as resolved by X-ray
crystallography (Oefner et al., 2009). Three of the mutations, colored red (F99Y, F99Y/L21V
& L41F), were previously shown to confer resistance to TMP, whilst the remaining four, colored
blue (F123L, A135T, V76A, I83V), remained susceptible to the action of the antibiotic (Gordon
et al., 2014). This classification was confirmed by independent measurement of TMP minimum
inhibitory concentrations for each mutant (Table S1 & S2). These colors are used throughout.
Our hypothesis is that chromosomal mutations in an open reading frame will confer resis-72
tance if the mutation causes the antibiotic molecule to bind less well to the encoded protein,73
whilst, crucially, not significantly affecting how well the natural substrate binds. This is only74
one of several mechanisms by which bacteria can evolve resistance to antibiotics (Blair et al.,75
2014). Other mechanisms include the introduction, by horizontal gene transfer, of genes en-76
coding either proteins that degrade antibiotics, for example b -lactamases which are common77
in gram-negative bacteria, or, as mentioned above, naturally resistant versions of chromosomal78
proteins. The over-expression of efflux pumps can reduce the concentration of the antibiotic79
within the bacterium to below effective levels or the cell well can simply be impenetrable to80
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most antibiotics, the most notable example of this beingM. tuberculosis.81
The binding free energy (DG) is the thermodynamic quantity that captures how strongly a82
small molecule, like an antibiotic, is bound to a protein. Our hypothesis therefore distills down83
to calculating how a specific mutation affects the binding free energies, relative to the wildtype84
(wt), of both TMP and DHA85
DDGTMP = DGmutantTMP  DGwtTMP
DDGDHA = DGmutantDHA  DGwtDHA
Whilst it would be trivial for a mutation to disrupt the binding of the antibiotic (i.e. DGmutantTMP >86
DGwtTMP and so DDGTMP > 0), it is difficult for a mutation to simultaneously not disrupt the bind-87
ing of the natural substrate (i.e. DGmutantDHA ⇠ DGwtDHA leading to DDGDHA ⇠ 0). For a mutation to88
give rise to a viable strain of S. aureus that is resistant to TMP a first estimate of a binding free-89
energy criterion is therefore is that DDGTMP > 0 and DDGDHA ⇠ 0. By making some simple90
assumptions and applying kinetic theory, we will relate these changes in binding free energies to91
the minimum inhibitory concentrations (MICs) of the antibiotics. This is the quantity measured92
by clinical microbiology laboratories, and we are able, through MICs distributions published93
by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), derive more94
sophisticated criteria based on clinical data.95
To calculate how the binding free energy of either the antibiotic or the natural substrate96
changes upon introduction of the mutation we will apply Hamiltonian-exchange thermody-97
namic integration, an alchemical free energy method (Fowler et al., 2005; Gilson and Zhou,98
2007; Fowler et al., 2007; Michel et al., 2010; Chodera et al., 2011; Gapsys et al., 2015a; Perez99
et al., 2016; Abel et al., 2017). Alchemical free energy methods are derived from classical sta-100
tistical mechanics and calculate the cost of perturbing a chemical moiety, such as an amino acid101
sidechain, into another using a series of classical molecular dynamics (MD) simulations; hence102
they are dubbed ‘alchemical’. There are no free parameters, and so in theory are exact, although103
in practice there are always likely to be errors due to imperfections in the parametrisation of the104
molecules and the incomplete exploration of the dynamical phase space of the system during105
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the simulations. We will not consider here other methods of calculating or estimating binding106
free energies, such as computational docking, ‘endpoint’ methods or protein design or stability107
algorithms, since they are unlikely, in our opinion, to capture the subtlety of the molecular per-108
turbations. Since each free energy calculated by an alchemical free energy method requires a109
number of molecular dynamics simulations, this approach potentially requires large amounts of110
computational resource; however, given the continued increase in computing speeds this class111
of methods is coming of age and is beginning to find application (Wang et al., 2015; Samsudin112
et al., 2016; Gapsys et al., 2016; Lenselink et al., 2016).113
Traditionally, a single calculation would be run for each perturbation (here a protein mu-114
tation) and the error in the free energy estimated by, e.g. dividing the simulation trajectories115
into ‘independent’ sections by calculating a correlation time. Since this is a clinically impor-116
tant problem where the accuracy of the classification, and potentially also minimising the time117
taken to return a prediction, are essential, we shall instead run a large ensemble of relatively-118
short thermodynamic integration calculations for each mutation, simplifying the estimation of119
confidence intervals, as well as, subject to having sufficient computational resource, potentially120
reducing the time to solution. In the second half of the paper we will estimate the sensitivity121
and specificity of our method.122
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RESULTS123
Clinically a mutation is described as resistant if the minimum concentration of an antibiotic124
that inhibits the growth of the bacteria is greater than a reference concentration. According to125
the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2016), S. aureus126
is defined as not susceptible to TMP (i.e. resistant) if its minimum inhibitory concentration127
(MIC) is   4 mg/l. Since TMP is a competitive inhibitor of DHFR and, assuming Michaelis-128
Menten enzyme kinetics (Price et al., 2009), then as shown in the Supplemental Information, if129
we assume that the mutation only affects the dissociation equilibrium constant of the antibiotic130
(Ki) we can derive a simple binding free-energy based resistance criterion,131
DDGTMP   0.8 kcal/mol. (R1)
132
This assumes that the enzyme rate constant and the concentrations of the enzyme and the sub-133
strate are all unaffected by the mutation. Alternatively, if we allow the protein mutation to affect134
the dissociation constants of both the inhibitor and the natural substrate, then we find a second135
resistance criterion,136
DDGTMP DDGDHA   0.8 kcal/mol. (R2)
137
This is a more nuanced view of how resistance can arise: resistance is conferred if a mutation138
increases how well the natural substrate binds (DDGDHA < 0), as well as decreasing how well139
the antibiotic binds (DDGTMP > 0). It is likely, however, that large changes in the magnitude of140
DDGDHA will affect the action and turnover rate of the enzyme and so, in practice, there will be141
a limit on how much a mutation can affect the binding of the natural substrate. Applying either142
of the above criteria generates a prediction of whether a mutation confers resistance or not and143
one of the aims of this paper is to assess if criterion R2 is more accurate and precise than R1. For144
either resistance criterion to classify a mutation as conferring resistance (or having no effect) the145
relevant free energy in R1 or R2 must be lie demonstrably one side of the 0.8 kcal/mol threshold146
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or the other; if the confidence limits bracket the threshold, then either criterion must return a147
classification of ‘unknown’. This is a small departure from most culture-based microbiology148
tests which simply return a binary ‘resistant’ or ‘susceptible’ classification.149
We chose a series of mutations in the chromosomal gene dhfB identified by whole-genome150
sequencing of S. aureus clinical infections from two hospitals in the UK (Gordon et al., 2014).151
As expected, by far the most common naturally occurring TMP resistance-conferring muta-152
tion in S. aureus DHFR was F99Y (Gordon et al., 2014; Dale et al., 1997). Several studies153
have shown that this common mutation reduces the binding free energy of TMP to S. aureus154
DHFR by 2.0 ± 0.2 kcal/mol (Dale et al., 1997; Oefner et al., 2009; Frey et al., 2010, 2012;155
Pires et al., 2015), equivalent to a 24 fold increase in the dissociation constant, Ki. This is a156
large effect given the mutation only replaces a hydrogen by a hydroxyl. Two further resistance-157
conferring mutations were chosen: L41F, which has also been previously observed (Vickers158
et al., 2009), and the double mutation F99Y/L21V, which has not – the related triple mutation159
F99Y/L21V/N60I was, however, identified as resistant 20 years ago (Dale et al., 1997). Mu-160
tating two residues simultaneously is likely to lead to convergence issues, and we therefore de-161
composed the double F99Y/L21V mutation into two separate mutations, F99Y and Y99L21V,162
summing the free energies to obtain the result for the double mutation (Klimovich et al., 2015).163
Although it has not yet been observed in isolation, we also calculated the effect of the iso-164
lated L21V mutation, allowing us to test the additivity of these mutations. Both the L41F and165
F99Y/L21V mutations are rare, only being observed once each among nearly 1,000 UK clin-166
ical isolates (Gordon et al., 2014). Any classification method must be able to distinguish true167
positives from true negatives, and therefore we also studied the effect of four mutations in S.168
aureus DHFR that were each detected multiple times in the isolate collection and had no effect169
on the action of TMP based on the results of conventional drug susceptibility testing. These170
were F123L, A135T, V76A and I83V (Fig. 1B) and are negative controls.171
To confirm the phenotype of these seven mutations and to provide a consistent quantitative172
dataset, a subset of the clinical isolates that were sequenced as part of the previous study (Gor-173
don et al., 2014) were retrieved and re-tested as described in the Methods. The TMPMICs were174
determined for each patient isolate (Table S1); up to five independent measurements were ob-175
tained, depending on how many clinical isolates of that mutation existed. The values obtained176
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agree well with both MIC values recorded by Public Health England during routine testing (Ta-177
ble S2) and those previously reported in the literature (Pires et al., 2015; Dale et al., 1997; Frey178
et al., 2010, 2012; Vickers et al., 2009).179
Alchemical free energy calculations accurately predict which mutations180
confer resistance181
Using our chosen alchemical free method (see Methods) we calculated how the free energy of182
binding of both TMP (DDGTMP) and DHA (DDGDHA) varies upon introducing each of the seven183
clinically-observed mutations. Thirty two values of DDGTMP and DDGDHA were calculated for184
each mutation, making 512 DDG values in total. Since each pair of (DDGTMP,DDGDHA) values185
necessitated the calculation of 13 different DG values (Fig. S5), that makes 3,328 separate free186
energies. Since they originate from separate sets of simulations, each DDG value is assumed187
to be independent, and therefore it is straightforward to examine how the values of DDGTMP188
and DDGDHA converge as the number of calculations, n, increases (Fig. 2). As expected, the189
uncertainty in the free energy is a maximum around n = 3 and then falls as the number of190
calculations is increased. The mutations with the largest confidence intervals are also those191
which perturb the largest number of atoms (F99Y/L21V, L41F and F123L).192
The above analysis assumes that each DDG calculation is itself converged; the standard way193
to test this would be to compare the forward and reverse cumulative averages of each DDG value194
(Yang et al., 2004; Klimovich et al., 2015). This is not possible here due to the large numbers195
of DDG values; instead we demonstrate that increasing or decreasing the proportion of each196
simulation that is discarded does not significantly alter either the calculated numerical values,197
or the resulting classification (Fig. S1 & S2).198
Whilst our predicted value of DDGTMP for the common F99Y mutation (1.5± 0.2 kcal/mol)199
Fig. 3A, Table S3) does not agree within error with the mean value (2.0 ± 0.2 kcal/mol) of200
several previously published isothermal titration calorimetry (ITC) measurements (Pires et al.,201
2015; Oefner et al., 2009; Dale et al., 1997; Frey et al., 2010, 2012), there is considerable over-202
lap between the predicted and experimental values. Furthermore, all three known resistance-203
conferring mutations (F99Y, F99Y/L21V and L41F) are predicted to reduce how well TMP204
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Figure 2: The calculated values for how the binding free energies change upon mutation (DDG)
converge as the number of independent thermodynamic integration calculations is increased.
Thirty-two separate calculations of DDGTMP and DDGDHA were run for each of the (A) three
resistance-conferring and (B) four susceptible mutation (Table S3, S4). For each mutation, the
variation in the mean DDG value and its 95% confidence limits (calculated using the appropriate
t-statistic) are shown as a function of the number of calculations, n. The inset graphs show how
the confidence limits vary with n and all have the same scale. The initial 20% of each simulation
has been discarded to avoid equilibration effects.
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binds to DHFR (DDGTMP> 0, Fig. 3B, Table S3). Since these mutations were predicted to,205
on average, increase DDGTMP by significantly more than 0.8 kcal/mol, they are classified as206
conferring resistance to TMP by criterion R1. Of the four negative control mutations, three are207
predicted to have ‘no effect’ on the action of TMP, although the 0.8 kcal/mol threshold is just208
outside the confidence limits for the F123L mutation. Since the 95% confidence limits for the209
remaining I83V mutation cross the threshold, this mutation is classified as having an ‘unknown’210
phenotype.211
But how do the mutations affect the binding of the natural substrate, DHA? In contrast to212
the binding of TMP, all the mutations, with the exception of L41F and I83V, are predicted to213
either have no effect on the binding of DHA, or to increase how strongly DHA binds to DHFR214
(Fig. 3C, Table S4). By considering the mean values for all four no-effect mutants, we find they215
are not predicted to change the magnitude of DDGDHA by more than 0.5 kcal/mol, in line with216
our expectation that DDGDHA⇠ 0.217
Plotting the mean values of DDGDHA against DDGTMP (Fig. 4) allows us to classify the218
seven mutations using the second resistance criterion (R2). This condition predicts that all219
three known resistance-conferring mutations confer resistance to TMP, whilst of the four neg-220
ative controls, three (V76A, A135T and I83V) are correctly predicted to have no effect on the221
action of TMP. Since the confidence limits of the remaining F123L mutation straddle the 0.8222
kcal/mol threshold, it is predicted to have an ‘unknown’ effect. If the natural substrate binds223
more strongly to the enzyme (DDGDHA< 0), one could hypothesise that this should improve224
the turnover rate, if binding is the rate-limiting step. We speculate that L41F and I83V (espe-225
cially the former) induce a fitness cost, since they reduce how well DHA binds to DHFR, whilst226
V76A, F99Y and particularly F99Y/L21V, bring a fitness benefit, with the others have no effect227
on the fitness of the enzyme. Since the free energies for the L21V and Y99L21V mutations228
(Table S3 & S4) are identical, to within error, we conclude that the effects of the F99Y and229
L21V mutations on the binding of TMP or DHA in the double F99Y/L21V mutant are additive230
.231
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Figure 3: Thermodynamic integration correctly calculates how much the F99Y mutation re-
duces the TMP binding free energy and the R1 resistance criterion correctly classifies 6 of
the 7 clinical mutations. (A) Whilst the predicted change in the binding free energy of TMP
(DDGTMP) due to the F99Y mutation does not agree with previously published experimental
data, the difference is small. (B) Applying resistance criterion R1 correctly classifies the F99Y,
F99Y/L21V and L41F mutations as conferring resistance to TMP. The mutation L21V is also
predicted to confer resistance. Of the four mutations known to have no effect on the action of
TMP, F123L, A135T and V76A are correctly classified as not conferring resistance and I83V is
classified as having an unknown effect. The fold change in the dissociation equilibrium constant
(Ki) is also shown. Each value of DDG is the mean of 32 independent calculations (Tables S3,
S4), and the bars represent 95% confidence limits, using the appropriate t-statistic. The initial
20% of each simulation has been discarded to avoid equilibration effects. Discarding 10% or
50% of the data does not alter these conclusions (Fig. S1 & S2 ). (C) The same calculations
were repeated, but with dihydrofolic acid (DHA) bound. With the exception of L41F and I83V,
no mutation decreases how well DHA binds to DHFR, to within error.
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Figure 4: The R2 resistance criterion correctly predicts the effect of six of the seven mutations,
with F123L being classified as having an unknown effect. (A) Plots of how each mutation is
predicted to affect the binding of DHA against TMP (i.e. Fig. 3B v. C) for each of the 32
independent pairs of calculations. The region defined by the R2 resistance criterion is shaded
grey. (B) Plotting the mean values with 95% confidence intervals demonstrates that the R2
resistance criterion correctly classifies all bar the F123 mutation which is predicted to have an
unknown effect. The variation with n is shown in Fig. S3. All mutations are colored according
to the same scheme as Fig. 1.
13
Predicting minimum inhibitory concentrations.232
A stronger test of our approach is to compare against quantitative, rather than qualitative, data233
for all the mutations tested, rather than just F99Y. In the absence of quantitative binding data234
for the other mutations (as measured by e.g. ITC), we can instead predict the MIC for each235
mutation using Equation S2 and then compare it to the experimentally observed mean MICs236
(Table S1). As described in the Methods, the TMP MICs were measured by bioMérieux E-237
test. These have a roughly-doubling ladder of antibiotic concentrations going from 0.002 to 32238
mg/L, a range of 16,000 fold. At first glance, there is a good correlation between the predicted239
and observed MICs (Fig. 5). This is, however, not a thorough test since (i) the experimental240
values have an upper limit of > 32 mg/ml and so we cannot distinguish between the different241
resistance-conferring mutations and (ii) there are no mutations that confer an intermediate level242
of resistance. Despite this, five of the seven predicted MICs can be said to be in ‘essential243
agreement’, since they are within a single doubling dilution (within the 2⇥ lines) of the refer-244
ence method value (ISO, 2007) and, overall, it is promising that it appears possible to predict245
MICs to within a factor of 2-4.246
We conclude that alchemical free energy methods are not only able to distinguish resistance-247
conferring mutations from susceptible mutations but also, by comparing to ITC data and MIC248
data, can make quantitatively accurate predictions, although more work is required before it249
will be possible to confirm that one can formally relate DDG values to MICs. This proof of250
principle also study suggests that a good level of confidence in the phenotype of a mutation can251
be obtained by only predicting the effect on the binding of the antibiotic (i.e. criterion R1), in252
this case trimethoprim.253
Classifying mutations using an alchemical free energy method is sensitive254
and specific.255
Given predictions made by this type of approach could, one day, be used to drive clinical deci-256
sion making, it is essential to establish the sensitivity and specificity of the method. First, let us257
assume that our sets of 32 pairs of DDGTMP and DDGDHA values per mutation are representative.258
The classification performance of the method can then be modelled by repeatedly drawing (with259
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Figure 5: Our predicted values of the minimum inhibitory concentration (MIC) of trimetho-
prim correlate moderately well with the experimentally measured MICs. The predicted values
are inferred from how the mutation alters the relative binding of trimethoprim (TMP) and dihy-
drofolic acid using Equation S4. Note that since the bioMérieux E-test does not measure above
32 mg/l, we have likewise cut off our predicted values at > 32 mg/l. The predicted mean MIC
for the F99YL21V mutation is very large (⇠ 2,400 mg/l) and therefore cannot be plotted in this
range. Clinically, a S. aureus DHFR mutation is classified as resistant if the TMPMIC  4 mg/l
(EUCAST, 2016); this region is shaded light grey. To aid interpretation, lines corresponding to
a perfect correlation, and within factors of 2⇥ and 4⇥ are drawn. Since our calculations only
yield a fold increase in the MIC, all the predicted MIC values are assumed to be relative to
a wildtype (geometric mean) MIC of 1.1 mg/l (EUCAST, 2016). The mutations are colored
according to the same scheme as Fig. 1.
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replacement) samples containing n values of DDGTMP and n values of DDGDHA and applying260
either resistance criterion to produce a classification. We repeated this bootstrapping approach261
10,000 times at each value of 2 n 32 and a summary of the results at five distinct values of262
n 2 {3,5,10,16,32} is shown in Fig. 6 (see also Fig. S4). Interestingly, even at small values of263
n, the method is unlikely to return an incorrect categorical prediction – the highest false cate-264
gorisation rate occurs when applying the R1 resistance criterion to the I83V mutation at n= 3,265
and even then our analysis suggests the method would have incorrectly classified this mutation266
as conferring resistance only 2.5 % of the time with an ‘unknown’ result being returned in 91%267
of cases. We conclude that the method is robust in the sense that once n is large enough for it to268
return a definite categorisation it is highly likely to be correct.269
The performance of a binary classification process is usually assessed by considering the270
true positive and true negative rates of detection, often referred to as the sensitivity and speci-271
ficity, respectively. These are given in Table 1. Since our approach gives a ternary classification272
(‘unknown’ in addition to ‘resistant’ and ‘susceptible’), there are two ways one can define the273
sensitivity and specificity. The difference rises from whether one includes the uncharacterised274
cases in the numbers of false positives and false negatives, or whether these cases can be ex-275
cluded, since the method has (correctly) not attempted a definitive classification. If we first276
consider the former, more conservative definition, then the sensitivities / specificities are rela-277
tively low at small values of n and increase with n, achieving 99.7 / 61.3% for the R1 resistance278
criterion and 78.6 / 72.8% for the R2 criterion at n= 10 before reaching 100.0 / 77.9% and 84.0279
/ 91.0% at n= 32, respectively (Table 1). However, the proportion of uncharacterised cases fall280
dramatically from 37% (55%) for the first (second) resistance criterion at n= 3, to 11% (13%)281
at n = 32. If all these cases are excluded then all the sensitivities and specificities are   98%,282
suggesting that (i) the increase in the conservative estimates of the sensitivities and specificities283
is entirely driven by the decrease in the proportion of uncharacterised cases and (ii) our previ-284
ous observation that the method rarely incorrectly classifies a mutation is correct. We conclude285
that the main effect of increasing the number of free energy calculations used in a prediction286
is increasing the likelihood that a definite classification will be made. We cannot, though, con-287
clude which resistance criterion is ‘better’ since both the R1 and R2 resistance criteria struggle288
to classify two mutations each (F123L & I83V and F123L & L41F, respectively), even at high289
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values of n. Difficulties in classifying a mutation are due to a combination of where it hap-290
pens to fall relative to the two free energy thresholds on the (DDGTMP,DDGDHA) plane (Fig.291
4, S3) and the variability between individual free energy calculations, which is related to the292
magnitude of the perturbation. The performance of either criteria therefore critically depends293
on which mutations have been selected to make up a test-set and, since we have only studied294
seven mutations, we cannot yet conclude which is preferable. Allowing a mutation to affect the295
binding of the natural substrate as well as the antibiotic is more elegant and hence one would296
expect the R2 resistance criterion to be more accurate, but it also requires 138 ⇥ the number of297
free energy calculations (Fig. S5).298
One final possibility is to use the classifications from both criteria to make an ensemble299
prediction. The cases where both resistance criteria agree are trivial; the key question is how to300
classify mixed classifications e.g. RU. Here we assume that a definitive classification (‘resistant’301
or ‘susceptible’) will overrule any ‘unknown’ classification and ‘resistant’ will overrule ‘sus-302
ceptible’. Hence if the results of applying the R1 and R2 resistance criteria can be represented303
as two letters, we shall define our ensemble rules for predicting resistance, susceptibility or un-304
known phenotypes as [RR,RU,UR,RS,SR], [SS,SU,US] and [UU], respectively. This ensemble305
method improves the classification performance, as measured by sensitivities and specificities306
(Table 1), for these seven mutations at least. It is, however, slightly unsatisfying since it weak-307
ens the link between the effect of the mutation on how well the antibiotic binds to the protein308
and the effectiveness of the drug.309
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Figure 6: Predicting whether a mutation confers resistance is accurate and robust. The data
in this figure were calculated by sampling-with-replacement and classifying 10,000 sets of n
values of DDGTMP and n values of DDGDHA for n 2 {3,5,10,16,32} A classification is then
made from each bootstrapped sample of free energies, and the results shown here as a function
of n, the number of measurements in each sample, depending on whether the (A) first or (B)
second resistance criterion was applied. (C) The results of applying both criteria and taking a
consensus is also shown. See Fig. S4. How well the R1 & R2 criteria classify each mutation
can be understood by considering the location and relative variations of each mutation on the
DDGDHA versus DDGTMP plane. This is shown in Fig. 4 for n = 32 and examples of how it
varies with n are shown in Fig. S3.
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(a) Resistance criterion R1. DDGTMP   0.8 kcal/mol
all excluding uncharacterised
n sensitivity specificity sensitivity specificity uncharacterised
3 70.3 % 53.8 % 100.0 % 98.5 % 37.5 %
5 90.8 % 57.9 % 100.0 % 99.1 % 25.4 %
10 99.7 % 61.3 % 100.0 % 99.7 % 19.4 %
16 100.0 % 66.6 % 100.0 % 99.9 % 16.7 %
32 100.0 % 77.9 % 100.0 % 100.0 % 11.1 %
(b) Resistance criterion R2. DDGTMP+DDGDHA   0.8 kcal/mol
all excluding uncharacterised
n sensitivity specificity sensitivity specificity uncharacterised
3 60.4 % 29.4 % 99.6 % 99.2 % 54.9 %
5 75.1 % 46.7 % 99.8 % 99.9 % 39.1 %
10 78.6 % 72.8 % 99.9 % 100.0 % 24.2 %
16 80.3 % 82.7 % 100.0 % 100.0 % 18.5 %
32 84.0 % 91.0 % 100.0 % 100.0 % 12.5 %
(c) Consensus. Taking (R1,R2) then: R=(RR,RU,UR), S=(SS,SU,US), U=UU
all excluding uncharacterised
n sensitivity specificity sensitivity specificity uncharacterised
3 82.3 % 59.3 % 99.8 % 98.4 % 28.6 %
5 96.8 % 68.0 % 99.9 % 99.2 % 17.3 %
10 100.0 % 79.5 % 100.0 % 99.8 % 10.2 %
16 100.0 % 86.8 % 100.0 % 99.9 % 6.6 %
32 100.0 % 94.3 % 100.0 % 100.0 % 2.8 %
Table 1: The expected proportion of classifications which would be returned with an ‘unknown’
phenotype decreases as the number of calculations, n, increases. The resulting sensitivities and
specificities also increase with n. Two sets are given; the latter excludes all classifications
with an unknown phenotype. All sensitivities and specificities are estimated by creating 10,000
samples of n values of DDGTMP and n values of DDGDHA by drawing-with-replacement from the
larger set of 32 calculations. Results are given for the (a) R1 and (b) R2 resistance criteria. (c)
Applying a consensus where any definitive ‘resistance’ or ‘susceptible’ classification overrules
any ‘unknown’ classification is optimal.
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DISCUSSION310
We have shown that alchemical free energy methods can predict whether mutations in S. aureus311
DHFR confer resistance or not to the antibiotic trimethoprim. This paves the way for the intro-312
duction of such structural-based predictivemethods into a genetics-based clinical microbiology313
service (Didelot et al., 2012; Köser et al., 2014) – allowing novel or insufficiently-characterised314
mutations to be assessed, thereby mitigating one of the key weaknesses of genetics-based clini-315
cal microbiology. The potential benefits of transitioning from laboratory- to genetics-based mi-316
crobiology in the clinical setting are large: a reduction in the time for drug susceptibility testing317
(especially for slow-growing pathogens such as Mycobacterium tuberculosis), automatic epi-318
demiological monitoring of the dispersal of specific resistance mechanisms and ever-decreasing319
cost. The switch to a genetics-based clinical microbiology will ultimately lead to increased pre-320
cision in antibiotic prescribing and reduced selection for antibiotic resistance. The clinical tran-321
sition has just begun: in early 2017 Public Health England adopted whole-genome sequencing322
for routine drug susceptibility testing for M. tuberculosis infections (Walker et al., 2017) and323
other countries look likely to follow suit.324
Establishing the accuracy and reproducibility of any predictive method is essential, espe-325
cially if it could ultimately drive decisions in a clinical setting. We emphasise the vital im-326
portance of (i) having negative controls, which here was enabled by a previous clinical whole-327
genome sequencing (WGS) study (Gordon et al., 2014), (ii) running multiple repeats, which328
has the additional benefit of simplifying the estimation of errors (Coveney and Wan, 2016), and329
(iii) systematically assessing the sensitivity and specificity of any method.330
Ultimately, for predictions made by a computational method such as ours to form part of331
an antimicrobial diagnostic workflow, it must satisfy the same standards as any new lab-based332
diagnostic method (ISO, 2007; U.S. Department of Health and Human Services Food and Drug333
Administration, 2009). The key metrics used to assess a new method are the major discrepancy334
(MD) rate (the proportion of cases where the reference method predicts the infection is sensi-335
tive to an antibiotic but the new method predicts it is resistant) and the very major discrepancy336
(VMD) rate (which is the proportion of cases the reference method predicts the infection is337
resistant but the new method predicts it is sensitive). For a diagnostic test to be approved by338
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the International Standards Organization, both the MD and VMD < 3%. As noted earlier, our339
method very rarely produces an incorrect definitive classification, and hence if ’unknown’ re-340
sults can be excluded, our method, based on the results in this paper, satisfies these criteria. For341
example, if we take a ‘worst’ case and consider only n= 3 then the VMD and MD for the first342
resistance criterion are 0.0 % & 1.6 %, respectively, whilst for the second resistance criterion343
the VMD and MD are 0.4 % & 0.8%. In making this comparison, we are not claiming that this344
method is sufficiently accurate for use in a clinical microbiology workflow for diagnosing an-345
tibiotic resistant infections – clearly many more mutations and proteins need to be tested – but346
rather, in combination with the sensitivity and specificity analysis, it does show that this method347
has the potential to predict the effect of novel and rare mutations on the action of antibiotics.348
That the very major discrepancy rate is generally low but the proportion of classifications349
that are returned with an ‘unknown’ phenotype falls as n, the number of free energy calculations350
used to make a prediction, increases, suggests that a sensible way of applying this method would351
be to initially run a small number of free energy calculations (say n= 5) and try classifying the352
effect of the mutation. If a definitive result is returned, our analysis suggests that it is probably353
correct and will not be altered by adding more data. Alternatively, if the method cannot classify354
the effect of the mutation, then one can run additional free energy calculations until a definitive355
’resistant’ or ’no effect’ classification can be made. In this way, some mutations would be356
classified very quickly, and others, like F123L or L41F, would take longer, as one would expect357
given the larger number of atoms being perturbed by the protein mutation.358
Our approach has several weaknesses. Firstly, it assumes we know at a molecular level how359
an antibiotic works, specifically that it is a competitive inhibitor of an essential gene and it is360
mutations in that gene that we wish to examine; this is often, but not always, true. Secondly,361
it requires a high resolution experimental structure of the relevant bacterial protein with the362
antibiotic bound. Although the structural coverage of many bacterial genomes has more than363
doubled in the last ten years, with some species now having the structures of over half their364
proteins determined (Khafizov et al., 2014), the structural coverage of many pathogenic species365
remains low. In common with all applications of classical molecular dynamics, we are making366
two further key assumptions; (i) that our description of the molecular interactions is sufficiently367
accurate and (ii) that we have adequately sampled the phase space of the molecules. The first368
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is mitigated somewhat since it is protein atoms that are perturbed in the alchemical free energy369
calculation, and the protein forcefield has been extensively optimised (unlike in drug discovery370
where the atoms of a ligand, which inevitably are less well described, are perturbed). The sec-371
ond is mitigated by repeating calculations and allowing neighbouring simulations to exchange372
their Hamiltonians according to a Metropolis criterion. It is also difficult to calculate the relative373
free binding energy for some mutations using alchemical free energy methods; those perturbing374
large numbers of atoms are, as we have seen for e.g. F123L, take longer to converge. Finally,375
unlike in drug discovery where binding free energies (or equivalently dissociation equilibrium376
constants) are reported and to which one can directly compare predicted values of DDG, there is377
a paucity of binding free energy measurements for antibiotics. Instead the discipline of clinical378
microbiology measures and reports MIC values. It is possible, as we have done here, to relate379
the MIC to how the binding free energy changes upon the introduction of the mutation, but this380
requires several assumptions and is necessarily less direct.381
Throughout this study we have calculated each component free energy (Equation S10 &382
Fig. S7) using the same number of l simulations for the same duration, regardless of what type383
of free energy is being calculated and the size of the mutation being studied. This is almost cer-384
tainly highly inefficient; in future work we will examine how to optimise our approach so that385
the minimum amount of computational resource is required to produce an accurate classification386
in the shortest time possible. This will include determining if a large number of relatively short387
simulations (as done here) is more accurate, at least when it comes to classifying, than a smaller388
number of longer simulations. Although some progress has been made in recent years examin-389
ing this question in the context of endpoint free energy methods (Coveney and Wan, 2016), it390
has not yet been addressed for alchemical free energy calculations in general. Finally, it is only391
through the successful application of our approach to other proteins in other clinically-important392
pathogens where resistance is increasingly a problem, that it will be possible to determine if our393
method, or another one like it also based on the chemistry and structure of proteins, could, one394
day, be integrated into a genetics-based clinical microbiology pipeline.395
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Significance396
The discovery of antibiotics was one of humanity’s greatest achievements in the twentieth cen-397
tury; however, the evolution of antibiotic resistance by pathogens now threatens many advances398
of modern medicine. There is an urgent need for improved diagnostic tools so that resistant399
infections can be identified and treated appropriately. Analysis of whole-genome sequence data400
generated on affordable high-throughput platforms has the potential to allow resistant infec-401
tions to be more rapidly and cheaply diagnosed in the clinic than conventional culture based402
approaches. A key limitation of this approach is that it cannot identify whether rare or previ-403
ously unseen mutations will be associated with drug susceptibility or resistance. Since many404
antibiotics are competitive inhibitors, we hypothesise that mutations that confer resistance re-405
duce how well the drug binds the target protein, whilst not significantly altering the binding free406
energy of the natural substrate. In this case, predicting whether a mutation confers resistance407
is equivalent to calculating the effect of the mutation on the binding free energies of both the408
antibiotic and the natural substrate. By relating these quantities to the standard clinical microbi-409
ology metric, the minimum inhibitory concentration (MIC), we are able to derive two different410
clinically-based criteria for classifying the effect of mutations and show that alchemical free en-411
ergy methods, a well-established class of methods from computational chemistry, can not only412
predict which mutations confer resistance to trimethoprim, but are also quantitatively accurate.413
[233/300 words]414
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STAR METHODS424
CONTACT FOR REAGENT AND RESOURCE SHARING425
Further information and requests for reagents may be directed to, and will be fulfilled by the426
corresponding author Philip Fowler427
EXPERIMENTAL MODEL AND SUBJECT DETAILS428
The clinical isolates tested in this study were collected and sequenced as described previously429
(Gordon et al., 2014).430
METHOD DETAILS431
Trimethoprim Susceptibility Testing432
Susceptibility of test isolates to trimethoprim was determined by E-test (bioMérieux, Marcy433
l’Etoile, France) in accordance with the manufacturer’s instructions. Breakpoints were inter-434
preted according to EUCAST guidelines (EUCAST, 2016).435
System building and equilibration436
An experimental structure of S. aureus DHFR with trimethoprim (TMP) and NADPH bound437
(PDB:3FRE) was used to setup all simulations (Oefner et al., 2009). Apo structures were438
created by removing TMP. The generalized AMBER forcefield in conjunction with AMBER439
ff99SB-ILDN (Lindorff-Larsen et al., 2010) was used throughout and all simulations were car-440
ried out using GROMACS 5.0.x (Abraham et al., 2015). The mutations in the protein were441
represented using a dual topology and all GROMACS free energy topology files were prepared442
using pmx (Gapsys et al., 2015b). Each protein was solvated by adding waters and ions resulting443
in a simulation unit cell of dimensions 7.1 ⇥ 6.4 ⇥ 6.0 nm containing 27,077–27,120 atoms.444
For each mutant, separate apo, TMP- and DHA-bound short equilibration simulations were run.445
First the energy of each system was minimised using the steepest descent algorithm for 1000446
steps, then the dynamics of the system evolved for 2.5 ns with an integration timestep of 1 fs.447
Electrostatic forces were calculated using the particle mesh Ewald method with a real space448
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cutoff of 1.2 nm. Van der Waals interactions were cutoff at 1.2 nm, with a switching function449
applied from 0.9 nm. A Langevin thermostat with a time constant of 2 ps was applied to keep the450
temperature at 310 K. The pressure was maintained at 1 atm by an isotropic Parinello-Rahman451
barostat with a time constant of 1 ps and a compressibility of 4.46⇥ 10 5 bar 1. The lengths452
of all bonds involving a hydrogen were constrained using the LINCS algorithm. Since all the453
above simulations were run with l = 0 (i.e. wildtype sidechain), we then ran a short simula-454
tion to ‘phase-in’ the mutant sidechain using the Alchembed procedure (Jefferys et al., 2015).455
This was repeated for different snapshots taken during the 2.5 ns equilibration trajectory and456
ensured that we had a range of starting conformations suitable for all the different alchemical457
and end-point simulations.458
Alchemical simulations and calculations459
A thermodynamic cycle was constructed (Fig. S7) and changes in the free energy of binding460
upon introduction of the mutation, DDG, was defined by a series of alchemical transformation461
free energies. We followed best practice and, when changing one sidechain into another, cal-462
culated three separate free energies (Klimovich et al., 2015). This was repeated first for the463
apo protein (DG1) and then the complex (DG6). First the electrical charges on the perturbing464
atoms are removed (DG11 & DG61), before the van der Waals terms on the disappearing and465
appearing atoms are decoupled and coupled to the system, respectively (DG12 & DG62), using466
a soft-core potential (Beutler et al., 1994; Zacharias et al., 1994). Finally the electrical charges467
on the new atoms are switched on (DG13 & DG63). To keep the ligand within the active site,468
the distance between the protein and ligand centres of mass were restrained using a harmonic469
potential with a spring constant of 2000 kJ nm 1 mol 2. The reference distances for TMP and470
DHA were 0.644 nm and 0.794 nm, respectively. The free energies of removing both restraints471
were calculated (DG5 & DG7). The final free energy is derived in the Supplemental Information472
and is given by473
DDG= DG5+(DG61+DG62+DG63)  (DG11+DG12+DG13) DG7. (1)
Each free energy was calculated by running either 8, 11 or 16 simulations at equally-spaced474
26
values of the progress parameter, l , between 0 and 1. To accelerate convergence, each set of 8,475
11 or 16 simulations were coupled and attempted to exchange Hamiltonians every 1,000 steps476
(Sugita et al., 2000; Woods et al., 2003). Each set was run for 0.25 ns, meaning each free energy477
calculation required between 26 and 52 ns of molecular dynamics simulation. Thirty two pairs478
of (DDGTMP,DDGDHA) were calculated for each mutation (Table S3 and Fig. S5), 5 with 11⇥l479
values, 5 with 16⇥l values and 22 with 8⇥l values. No correlation between the number of l480
values and the magnitude of the resulting value of DDG was detected. Calculating 32 pairs of481
DDG values for a single mutation therefore required 1.0 µs of molecular dynamics simulation.482
Eight mutations were calculated in total (since the F99YL21V mutation was decomposed into483
two separate mutations), making a total of 8.1 µs of molecular dynamics simulation. More484
daunting is that this is composed of 32,344 separate molecular dynamics simulations. These485
were stored and discovered using datreant, a flexible python module for handling heteroge-486
neous file-based data (Dotson et al., 2016).487
The first derivative of the internal energy at the specified value of l , as well as the internal488
energy evaluated at all other values of l were written to disc every 0.1 ps. This permitted the489
free energy (DG) to be calculated using either the multi-state Bennett acceptance ratio estimator490
(MBAR) (Shirts and Chodera, 2008) by the alchemical-analysis python module (Klimovich491
et al., 2015), or simple thermodynamic integration. Since no significant differences in DDG492
values were observed, with the mean unsigned error in a value of DDG being between 0.1-0.3493
kcal/mol, depending on the number of atoms being perturbed, the latter was used for simplicity.494
A subset of the GROMACS input files is available for download allowing a single pair of DDG495
values to be calculated for each mutant from https://github.com/philipwfowler/amr-free-energy-496
dhfr-examples.497
The simulation parameters are the same as for the equilibration simulations above, except498
the tolerance factor for the Ewald sum is decreased to 10 6 to increase the accuracy of calculat-499
ing electrostatic forces, as is standard in these types of calculations. To remove transient effects,500
the first 20% of each simulation was discarded. Discarding more (50%) or less (10%) of the501
data did not materially affect the results (Fig. S2).502
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QUANTIFICATION AND STATISTICAL ANALYSIS503
Throughout, standard errors were calculated at a confidence level of 95%, taking into account504
the appropriate t-statistic for the sample size. This assumes each calculated value of DG is505
independent, which is reasonable since they are started from different initial structures taken506
from the equilibration simulations and run using different random seeds.507
DATA AND SOFTWARE AVAILABILITY508
The clinical isolates tested in this paper were sequenced in a previous study (Gordon et al., 2014)509
and, as a result, can be found in the European Nucleotide Archive Sequence Read Archive under510
study accession number ERP004655.511
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Mutation measured MICs mean MIC MIC range Phenotype DDDGTMP DHA
(mg/l) (mg/l) (95% confidence) (kcal/mol)
F99Y >32, >32, >32, >32, >32 >32 – Resistant > 2.1
F99Y/L21V >32 >32 – Resistant > 2.1
L41F 32 32 – Resistant 2.1
F123L 0.5, 0.5, 0.5 0.5 – Susceptible -0.5
A135T 0.38, 0.38, 0.5, 0.75, 1 0.6 0.3-0.9 Susceptible -0.4 ± 0.3
V76A 0.38, 1, 1, 1, 1 0.9 0.4-1.5 Susceptible -0.2 ± 0.4
I83V 0.5, 0.5, 0.75, 0.75, 1 0.7 0.5-1 Susceptible -0.3 ± 0.2
Table S1: Related to Figure 1. The trimethoprim minimum inhibitory concentrations (MIC), as measured by bioMe´rieux
E-test, for the seven mutations chosen for this study. The F99Y/L21V and L41F mutations were only observed once, and
hence each only has a single data point. Likewise the F123L mutation was only observed three times. For all other mutations
five randomly-selected clinical isolates were tested as described in the Methods. The average MIC was calculated using the
geometric mean and 95% confidence intervals are estimated using the appropriate t-statistic. The measured phenotypes are
consistent with the previously published study (Gordon et al., 2014).
Mutation PHE MIC values data (mg/l)
F99Y >32, >32
F99Y/L21V –
L41F –
F123L 0
A135T 0
V76A 0, 0, 0, 0, 1
I83V 0, 0, 1
Table S2: Related to Figure 1. The incidences and recorded trimethoprim minimum inhibitory concentrations (MIC) by
routine monitoring by Public Health England (PHE). Neither the F99Y/L21V or L41F mutation were observed. All isolates
containing any of the plasmid-encoded genes, dfrA, dfrG or dfrK, were excluded.
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Figure S4: Related to Figure 6. Increasing the number of independent calculations improves the classification by either
resistance criteria. (A) Using the first resistance criterion, if a small number of calculations (< 5) are run there is a small
chance of susceptible mutations being classified as resistant and a moderate chance of any mutation being classified as having
an unknown phenotype. As the number of calculations is increased past 10, these errors disappear and all mutations are either
correctly classified (as resistant or susceptible), or an unknown result is returned. The chance of an unknown phenotype being
returned falls steadily as the number of calculations increases, until at n = 32, we predict that five of the seven mutations,
would always be correctly classified and an ‘unknown’ result would be returned for F123L and I83L around half the time. (B)
The picture is similar if we apply the second resistance criterion, except that now it struggles to correctly classify the F123L
and L41F mutations. Again there is a small chance of a classification error when n < 5, which disappears as n increases.
The differences that arise from applying these two resistance criteria can be explained by considering where the mutations are
found on the DDGDHA v. DDGTMP plot (Fig. 4) in relation to the lines that define both resistance criteria. (C) We can improve
the performance slightly if we apply both resistance criteria, examine both results and allow any definitive classification
(‘resistant’ or ‘susceptible’) to overrule any ‘unknown’ classification.
Supplemental Theory
Relating binding free energies to minimum inhibitory concentrations
Since it is known that trimethoprim is a competitive inhibitor of DHFR and, if we assume the action of DHFR can be described
by Michaelis-Menten enzyme kinetics using the simple scheme in Fig. S5A, then the rate of product formation, v, is given by
v= kcat[E]0
[S]
KM +[S]
where kcat is the enzyme rate constant, [E]0 is the total concentration of the enzyme (DHFR), [S] is the concentration of the
substrate (DHA) and KM is the Michaelis-Menten constant (Price et al., 2009). The effect of a competitive inhibitor, such as
trimethoprim, is to increase the apparent magnitude of KM according to
K0M =
✓
1+
[I]
Ki
◆
KM
where [I] is the concentration of the inhibitor (TMP) and Ki its dissociation constant (Price et al., 2009). By definition, when
the concentration of the inhibitor, [I], is equal to the MIC then the rate of product formation, v, is a constant and is small
enough to prevent bacterial growth. If we assume that mutating DHFR does not alter the the enzyme rate constant (kcat), or
the concentrations of the enzyme ([E]0) and the substrate ([S]) then by equating the rates of product formation for the wildtype
(wt) and mutated enzymes at their respective MICs we find that✓
1+
MICwt
Kwti
◆
KwtM =
✓
1+
MICmutant
Kmutanti
◆
KmutantM
Given the known values of the MIC and published data on Ki for DHFR (Oefner et al, 2009; Frey et al., 2010), we find that,
in general, MIC  Ki, and therefore this simplifies to
MICwt
MICmutant
=
Kwti
Kmutanti
.
KmutantM
KwtM
.
The simplest case is to assume that mutating DHFR only alters the dissociation constant of the inhibitor (Ki, the antibiotic
TMP), then
MICwt
MICmutant
=
Kwti
Kmutanti
.
Since the free energy of binding is related to the dissociation constant via
DG= kT ln(Ki/c   ), (S1)
where k is Boltzmann’s constant, T is the temperature and c    is the standard concentration, then we can rewrite the above as
MICwt
MICmutant
= exp
✓
DGwtTMP DGmutantTMP
kT
◆
= exp
✓
DDGTMP
kT
◆
(S2)
where DDGTMP = DGwtTMP DGmutantTMP is how the mutation affects the binding free energy of TMP, k is Bolzmann’s constant
and T is the temperature. The geometric mean MIC for wildtype trimethoprim in S. aureus is 1.1 mg/ml (EUCAST, 2016),
therefore for a mutation in S. aureus DHFR to be clinically defined as resistant,
DDGTMP   0.8 kcal/mol, (R1)
which is equivalent to increasing Ki at least 3.6⇥. This is the first criterion for classifying a mutation as causing resistance,
and is therefore labelled R1, as in the main body of the paper.
Alternatively, we may allow the mutation to alter the dissociation constants of both the substrate (in effect altering KM)
and the inhibitor. By definition,
AB
C
⇌ →
⇌
ESE+S+ I
EI
E+P
k1
k 1
k 2 k2
kcat
KM =
k1+ kcat
k 1
Ks =
k1
k 1
Ki =
k2
k 2
Distance 
restraints Mutation
Wildtype
Mutation
Wildtype
Wildtype
Mutation
remove 
restraints
remove 
restraints
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DHFR } DHFRDG11 DG12 DG13
DG62 DG63DG61
}DG6 = DG61+DG62+DG63
DG1 = DG11+DG12+DG13DG4 DG2
DG7 DG5
DG3
Trimethoprim
decharge decouple recharge
D
Figure S5: Related to the STAR Methods. (A) A simple kinetic scheme for the competitive inhibition of an enzyme, E, by
an inhibitor, I. The enzyme binds with a substrate, S, to produce an intermediate, ES, which then reacts yielding the product,
P, and the enzyme. Each step is labelled with forward and, where appropriate, reverse rate constants. (B) The Michaelis-
Menten constant is defined in terms of three rate constants. (C) The dissociation constants of the inhibitor, Ki, and substrate,
Ks. (D) The thermodynamic cycle used to calculate how the binding free energy of either trimethoprim or dihydrofolic acid
changes (DDG) when a mutation is introduced into S. aureus DHFR. In the alchemical transitions (i.e. when one amino acid
is transformed into another) we remove all the electrical charges on the atoms that are being perturbed, before vanishing and
appearing the atoms necessary to make the mutation before finally recharging the resulting atoms. A free energy is therefore
calculated separately for each step (e.g. DG11). A soft-core van der Waals potential is used throughout. To prevent the ligand
unbinding from the protein during the simulations, a restraining potential is applied. The free energy of removing this potential
is calculated for both the wild-type and mutant proteins. Hence, a total of eight alchemical free energy calculations are needed
for each value.
KM =
k 1+ kcat
k1
(S3)
where the various rate constants are defined in Fig. S5A. If we assume that kcat ⌧ k 1 and define the dissociation equilibrium
constant of the substrate as Ks =
k 1
k1
, then
MICwt
MICmutant
=
Kwti
Kmutanti
.
Kmutants
Kwts
.
Again writing this in terms of binding free energies,
MICwt
MICmutant
= exp
✓
(DGwtTMP DGmutantTMP )  (DGwtDHA DGmutantDHA )
kT
◆
= exp
✓
DDGTMP DDGDHA
kT
◆
(S4)
which implies that for a mutation to be classified as resistant,
DDGTMP DDGDHA   0.8 kcal/mol (R2)
Resistance criteria R1 and R2 provide two different approaches for operationally testing to see if a DHFR mutation confers
resistance to TMP. These are labelled R1 and R2, respectively, in all figures and in the main body of the paper.
Calculating differences in binding free energies using alchemical transformations.
How the binding free energy of a ligand, such as trimethoprim, changes when a mutation is introduced into S. aureus DHFR
is simply the difference in the binding free energies of the ligand to the wild-type and mutant proteins (Fig. S5D).
DDG= DG2 DG4 (S5)
Since free energy is a thermodynamic state function, and is therefore independent of the path taken to calculate it, we can
construct a thermodynamic cycle such as shown in Fig. S5D. By definition
DG1+DG2 DG3 DG4 = 0 (S6)
hence we can rewrite Equation S5 as
DDG= DG3 DG1. (S7)
This is the difference between the free energies of introducing the mutation into the protein-ligand complex and the apo
protein and, although unphysical, is exact and computationally more tractable. This calculation assumes, however, that the
ligand remains bound during all simulations that contribute towards DG3, which since we are exploring mutations we believe
to weaken how well the ligand (in our case an antibiotic) binds to the protein, may not always hold. We therefore also applied
a simple harmonic restraint to keep the ligand in the binding site. The cost of removing this restraint must be calculated, and
so we construct a second thermodynamic cycle below the first. For this
DG3 DG5 DG6+DG7 = 0 (S8)
which when we combine with Eqn. S7 gives us the final result
DDG= DG5+DG6 DG1 DG7. (S9)
Or writing it out in full:
DDG= DG5+(DG61+DG62+DG63)  (DG11+DG12+DG13) DG7. (S10)
We note that calculating a single value of DDG for trimethoprim requires eight independent free energy calculations, however,
calculating a single value of DDG for the natural substrate, DHA, only requires an additional five free energy calculations since
the free energies for introducing the mutation into the apo protein (DG11,DG12,DG13) can be re-used. The computational cost
of testing the second criterion (R2) is therefore 1.625⇥ that of testing the first criterion, assuming all free energies require the
same amount of computational resource.
